Shares of Novacyt SA (LON: NCYT) today surged 10.8% after the company reported a significant jump in H1 2020 profits driven by rising demand for COVID-19 tests.
The company, which produces clinical diagnostics tools made a profit of €40.2 million ($47.5 million) before taxes during the six month period as compared to the 2.0 million loss reported during a similar period last year.
The company’s sales rose more than ten times to reach €72.4 as compared to last year.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
High demand for Novacyt’s PCR COVID-19 test was the main driver behind the company’s positive results.
The firm repaid all its outstanding debts and made a major investment in its inventory, yet it was left with €19.7 million in cash flow as of June 30.
The company also revealed that it had adopted a new strategy to maintain its current growth trajectory by extending its portfolio to include respiratory and transplant clinical diagnostics.
The firm said that the orders made for its COVID-19 product portfolio so far indicate that H2 2020 results could exceed H1 results.
Novacyt share price
Novacyt shares surged 10.8% today to trade at 410p having closed Wednesday’s session trading at 370p.
People who read this also read:
